微卫星杂合性缺失与甲状腺癌相关性研究  

Study on the correlation between the loss of microsatellite heterozygosity and thyroid carcinoma

作　　者：郭怀斌[1] 翟瑜[1] 苏力[2] 脱红芳[1] 郭贵军[1] 王春城[1] 暴雷[1] 

机构地区：[1]河北省人民医院普外三科,石家庄市050051 [2]河北省人民医院老年病三科,石家庄市050051

出　　处：《河北医药》2009年第17期2210-2212,共3页Hebei Medical Journal

基　　金：河北省科学技术研究与发展攻关计划项目资助课题(编号:062761203)

摘　　要：目的探讨特定位点微卫星杂合性缺失(LOH)与人甲状腺癌发生、临床病理特征及预后的关系。方法选取THRA1,D2S123,D11S912,BAT-264个位点,应用聚合酶链反应(PCR)和变性聚丙烯酰胺凝胶电泳技术,对30例甲状腺癌中LOH表达情况进行研究,术后随访5年,了解预后。结果THRA1,D2S123,D11S912,BAT-26四个位点LOH的检出率分别为33.3%,26.7%,23.3%和16.7%。术后随访5年,LOH阳性的甲状腺癌较阴性者生存期更长(P<0.05)。结论LOH导致基因组不稳定,在甲状腺肿瘤发生过程中发挥作用。Objective To investigate the correlation between the loss of microsatellite heterozygosity （LOH） and thyroid carcinoma, and to explore the relationship between the clinical pathological features of thyroid carcinoma and patients＇ prognoses. Methods The 4 sites including THRA1, D2S123, D11S912, BAT-26 were selected,and polymerase chain reaction （PCR） and denaturing polyacrylamide gel electrophoretic technique were used to detect the expression of LOH in 30 patients with thyroid carcinoma. The patients ＇ prognoses were evaluated by 5-year follow-up. Results The detection rates of LOH at the 4 sites including THRA1, D2S123, D11 $912, BAT-26 were 33.3% （20/60） ,26.7% （16/60） ,23.3% （14/60） and 16.7% （10/60） respectively. After 5-year follow-up, the survival time in patients with positive LOH was much longer than that of patients with negative LOH（ P 〈 0.05）. Conclusion LOH leads to the instability of the genome, which may result in the genesis of thyroid caicinoma. The patients with positive LOH have longer survival time.

关 键 词：甲状腺肿瘤 微卫星杂合性缺失 聚合酶链反应 

分 类 号：R736.1[医药卫生—肿瘤]